Literature DB >> 33663121

Electrophysiological study and radiofrequency ablation of hemodynamically-instable ventricular arrhythmias in a patient with pulmonary hypertension: A case report.

Song Zou1, Zhifu Cen1, Ruikun Jia1, Sijie Lu1, Yan Hao2, Kaijun Cui1.   

Abstract

INTRODUCTION: Hemodynamically-instable ventricular arrhythmias (VAs) are rare in patients with pulmonary hypertension (PH). To the best of our knowledge, only 1 case has been reported so far. Moreover, the pathogenesis of this kind of arrhythmia remains obscured and its treatment is challenging. Here we report another case and presented the substrate for VAs initiation and therapeutic effect of radiofrequency ablation. PATIENT CONCERNS: This is a 57-year-old man who presented paroxysmal palpitation associated with presyncope at rest. Surface electrocardiogram (ECG) revealed frequent ventricular premature contractions and non-sustained ventricular tachycardia when symptoms occurred. He also had a history of severe PH which was secondary to atrial septal defect and partial anomalous pulmonary venous drainage and suffered from obvious dyspnea when climbing stairs World Health Organization Class III (WHO Class III). DIAGNOSIS: Hemodynamically-instable VAs associated with severe PH. INTERVENTION: Echocardiography revealed enlargement of right ventricle (right ventricle [RV]: 43 mm). Electrophysiological examination showed the origin of VAs is next to a small low-voltage zone of RV. Radiofrequency delivery at the origin successfully terminated VAs without occurrence of complication. OUTCOME: The patient was free from arrhythmias and got an improvement of exercise tolerance, just with mild dyspnea when climbing stairs World Health Organization Class II (WHO class II), during six-month follow up. LESSONS: This case suggests the low-voltage zone of remodeled RV, which may be secondary to increased pulmonary artery pressure, serves as the substrate for VAs initiation in patient with PH. Radiofrequency ablation can successfully terminate VAs and the termination of VAs can significantly improve the patient's impaired exercise tolerance.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 33663121      PMCID: PMC7909233          DOI: 10.1097/MD.0000000000024896

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  11 in total

1.  Dispersion durations of P-wave and QT interval in children with congenital heart disease and pulmonary arterial hypertension.

Authors:  Fatih Sap; Zehra Karataş; Hakan Altin; Hayrullah Alp; Bülent Oran; Tamer Baysal; Sevim Karaarslan
Journal:  Pediatr Cardiol       Date:  2012-09-13       Impact factor: 1.655

2.  Spontaneous ventricular fibrillation in right ventricular failure secondary to chronic pulmonary hypertension.

Authors:  Soban Umar; Jong-Hwan Lee; Enno de Lange; Andrea Iorga; Rod Partow-Navid; Aneesh Bapat; Arnoud van der Laarse; Rajeev Saggar; Rajan Saggar; Dirk L Ypey; Hrayr S Karagueuzian; Mansoureh Eghbali
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-12-22

3.  Arrhythmogenic substrate in hearts of rats with monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.

Authors:  David Benoist; Rachel Stones; Mark Drinkhill; Olivier Bernus; Ed White
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-11       Impact factor: 4.733

4.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

5.  Right ventricular electrical remodeling and arrhythmogenic substrate in rat pulmonary hypertension.

Authors:  Yoshihiro Tanaka; Bonpei Takase; Takashi Yao; Masayuki Ishihara
Journal:  Am J Respir Cell Mol Biol       Date:  2013-09       Impact factor: 6.914

6.  Arrhythmias in adult patients with congenital heart disease and pulmonary arterial hypertension.

Authors:  Sabine Ernst; Konstantinos Dimopoulos; Maria Drakopoulou; Heba Nashat; Aleksander Kempny; Rafael Alonso-Gonzalez; Lorna Swan; Stephen J Wort; Laura C Price; Colm McCabe; Tom Wong; Michael A Gatzoulis
Journal:  Heart       Date:  2018-05-18       Impact factor: 5.994

7.  Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy.

Authors:  Stefano Ghio; Silvia Pica; Catherine Klersy; Eleonora Guzzafame; Laura Scelsi; Claudia Raineri; Annalisa Turco; Sandra Schirinzi; Luigi Oltrona Visconti
Journal:  Open Heart       Date:  2016-05-09

8.  Irregular wide QRS complex tachycardia in a patient with pulmonary hypertension: What is the mechanism?

Authors:  Abigail Louise D Te; Fa-Po Chung; Yenn-Jiang Lin; Shih-Ann Chen
Journal:  HeartRhythm Case Rep       Date:  2015-10-20

9.  Prognostic Relevance of Nonsustained Ventricular Tachycardia in Patients with Pulmonary Hypertension.

Authors:  Dirk Bandorski; Harilaos Bogossian; Johanna Stempfl; Werner Seeger; Matthias Hecker; Ardeschir Ghofrani; Reinhard Hoeltgen; Henning Gall
Journal:  Biomed Res Int       Date:  2016-12-20       Impact factor: 3.411

10.  Atrial arrhythmias are associated with increased mortality in pulmonary arterial hypertension.

Authors:  Benjamin Smith; Michael V Genuardi; Agnes Koczo; Richard H Zou; Floyd W Thoma; Adam Handen; Ethan Craig; Caroline M Hogan; Timothy Girard; Andrew D Althouse; Stephen Y Chan
Journal:  Pulm Circ       Date:  2018-07-03       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.